Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals

Summary, in English

Kaposi sarcoma-associated herpesvirus (KSHV) is the most important etiopathological factor of Kaposi's sarcoma (KS) and some specific types of malignant lymphomas. One of the viral lytic genes encodes the KSHV complement control protein (KCP), which functionally mimics human complement inhibitors. Although this protein provides an advantage for evading the complement attack, it can serve as target for adaptive immune response. Herein, we identified anti-KCP IgG antibodies in patients with KS and KSHV-related lymphomas. KCP-specific antibodies were only detected in sera of those patients who had high titres of antibodies against lytic or latent KSHV antigens. Complement control protein domain 2 (CCP2) was found to be the most immunogenic part of the KCP protein. Furthermore, pre-incubation of KCP-expressing CHO cells with patient sera containing anti-KCP antibodies resulted in an increased complement deposition when incubated with human serum.

• Author: Marcin Okroj; O Brad Spiller; Zoltan Korodi; Rosamaria Tedeschi; Joakim Dillner; Anna Blom
• Department/s: Clinical Chemistry, Malmö; Protein Chemistry, Malmö; Clinical Microbiology, Malmö
• Publishing year: 2007
• Language: English
• Pages: 8102-8109
• Publication/Series: Vaccine
• Volume: 25
• Issue: 48
• Links: http://dx.doi.org/10.1016/j.vaccine.2007.09.046
• Document type: Journal article
• Publisher: Elsevier
• Topic: Medicinal Chemistry; Microbiology in the medical area; Other Basic Medicine
• Keywords: Complement; Kaposi sarcoma; HIV; Lymphoma; Antibodies
• Status: Published
• Research group: Clinical Chemistry, Malmö; Protein Chemistry, Malmö; Clinical Microbiology, Malmö
• ISBN/ISSN/Other: ISSN: 1873-2518